Medication info

Sitax XR 25 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›28.345mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Pink, round, film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2), 30 tablets/bottle, 100 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 202007522 · Approved 2020.11.03

This product's status changed to Approval withdrawn on 2025.05.12. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General precautions). Patients with renal impairment Since dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically after starting this medicine. 1. No dose adjustment is required for patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required for patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Blood glucose control issues in type 2 diabetes patients
View approved original text

This drug is used to enhance blood glucose control in patients with type 2 diabetes alongside dietary and exercise therapies. It can be administered alone or in combination with other medications to improve therapeutic effects. This helps patients manage their blood glucose levels more effectively.

How to take

Adult dose

This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General precautions). Patients with renal impairment Since dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically after starting this medicine. 1. No dose adjustment is required for patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required for patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication may cause severe allergic reactions; if symptoms such as rash or difficulty breathing occur, discontinue use immediately and consult a physician. During treatment, there is a risk of developing severe pancreatitis; therefore, if experiencing symptoms such as abdominal pain, vomiting, or fever, immediately inform healthcare personnel. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication, and those with allergies to this drug or its components should avoid it. Patients with reduced kidney function may require dosage adjustments, and appropriate dosages should be determined through kidney function tests. While taking this medication, side effects such as cold-like symptoms, headaches, indigestion, and diarrhea may occur; if symptoms are severe, consult healthcare personnel. When taken with other glucose-lowering agents or insulin, there is an increased risk of hypoglycemia; appropriate measures should be taken if hypoglycemic symptoms appear. This drug can cause severe joint pain or blistering skin conditions; if these symptoms occur, discontinue usage immediately and consult a physician. Pregnant or breastfeeding women are advised not to take this medication, and safety in children under 18 has not been established. Elderly patients may experience reduced kidney function, so regular monitoring of kidney function before and after taking this drug is recommended. In case of overdose, general treatments such as removing the drug from the gastrointestinal tract are implemented, and some medications may be removed through hemodialysis.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory tract infections
  • nasopharyngitis
  • headache
Show 29 more
  • diarrhea
  • abdominal pain
  • nausea
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • blistering dermatitis herpetiformis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased blood triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air and moisture from entering. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius. This helps maintain the drug's effectiveness and safety.

Appearance and packaging

Appearance

Pink, round, film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2), 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.